Inovio running PHI/II trial with Genentech PD-L1 mAb

Inovio Pharmaceuticals Inc. (NASDAQ:INO) will conduct a Phase Ib/II trial evaluating its INO-5401 and INO-9012 in combination with PD-L1 mAb Tecentriq atezolizumab from Genentech Inc. (South San Francisco, Calif.) to treat advanced unresectable or metastatic urothelial carcinoma. The open-label trial is expected to begin this year and will enroll about 80 patients...